EP2934700B1 - A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin - Google Patents

A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin Download PDF

Info

Publication number
EP2934700B1
EP2934700B1 EP13815480.2A EP13815480A EP2934700B1 EP 2934700 B1 EP2934700 B1 EP 2934700B1 EP 13815480 A EP13815480 A EP 13815480A EP 2934700 B1 EP2934700 B1 EP 2934700B1
Authority
EP
European Patent Office
Prior art keywords
skin
composition
hatching
filtrate
fish
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13815480.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2934700A2 (en
Inventor
Hans Kristian Leren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqua Bio Technology ASA
Original Assignee
Aqua Bio Technology ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqua Bio Technology ASA filed Critical Aqua Bio Technology ASA
Publication of EP2934700A2 publication Critical patent/EP2934700A2/en
Application granted granted Critical
Publication of EP2934700B1 publication Critical patent/EP2934700B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to methods of preparing a composition comprising polypeptides or portions of polypeptides, which is derivable from fish hatching fluid, and its use in various applications to the skin.
  • the composition is useful for altering, preferably improving, the cosmetic appearance of aged skin.
  • the skin is one of the more vulnerable organs of the body. Skin is in constant interaction with external stimuli, directly or indirectly, and is frequently exposed to, and affected by, environmental agents. In fact, the skin can be seen as the first point of contact with the outside world. This constant exposure can result in unpleasant and/or unwanted physical and visible changes to the skin, particularly to the cosmetic appearance of skin. Whilst such changes may not threaten the health of an individual, such changes may be physically uncomfortable or visibly disagreeable. Indeed, because the skin is so visible, changes to the appearance of skin can lead to psychological stress. There is therefore a continuing need and demand for effective treatments to maintain, restore or improve the condition of the skin, and in particular to restore the youthful appearance of skin.
  • Skin forms the largest organ of the body, accounting for about 12-16 per cent of a person's weight. It performs many vital roles as both a barrier and a regulating influence between the outside world and the controlled environment within our bodies.
  • Skin consists of 3 layers, namely the epidermis, dermis and subcutis.
  • the epidermis is the uppermost, epithelial layer of the skin. It acts as a physical barrier, preventing loss of water from the body, and preventing entry of substances and organisms into the body. Its thickness varies according to body site.
  • the epidermis consists of stratified squamous epithelium, i.e. it consists of layers of flattened cells. Skin, hair and nails are keratinised, meaning they have a dead, hardened hydrophobic surface made of a protein called keratin. Epidermis is made impermeable due to its contents of extracellular lipids associated with keratinocytes, especially in the middle layer of the epidermis (stratum lucidum). Mucous membranes (e.g. of the oesophagus, oral pharyngeal cavity, reproductive organs, and others) are mainly non-keratinised and moist.
  • the epidermis has three main types of cell, namely keratinocytes (skin cells), melanocytes (pigment-producing cells) and Langerhans cells (immune cells).
  • the Merkel cell is a fourth, less prevalent, epidermal cell.
  • the keratinocytes mature and differentiate with accumulation of keratin as they move outwards. They eventually fall or rub off. They form four or five distinct strata, which from the most superficial to the deepest are (i) the Stratum corneum (horny layer) with dead, dried-out hard cells without nuclei, (ii) the Stratum granulosum (granular layer) with cells containing basophilic granules and outwardly separated from stratum corneum by the thin stratum lucidum, (iii) the Stratum spinulosum (spinous, spiny or prickle cell layer) in which the cells become increasingly flattened as they move upward and (iv) the Stratum basale (basal layer) with columnar (tall) regenerative cells.
  • the basement membrane a specialised structure that lies between the epidermis and dermis.
  • the dermis is the fibrous connective tissue or supportive layer of the skin.
  • the major fibres are collagen fibres and elastin which are interwoven.
  • the subcutis is the fat layer immediately below the dermis and epidermis. It is also called subcutaneous tissue, hypodermis or panniculus.
  • the subcutis mainly consists of fat cells (adipocytes), nerves and blood vessels.
  • New epithelial skin cells are created in the skin's lower layer, the stratum granulosum. Over time, cells migrate to the surface of the skin and become more acidic. During their 30 day journey, they die and become saturated with keratin. Keratin and associated lipids are important because they protect the skin from outside elements.
  • Age related deterioration in the cosmetic appearance of skin is a universal factor, particularly photoageing, i.e. Dermatoheliosis. This deterioration can be seen in irregularities or abnormalities in the skin, which may appear as, e.g. dry skin, wrinkles, fine lines, increased laxity (sagging) or altered pigmentation.
  • Photoageing is a term used for the characteristic changes induced by chronic UVA and UVB exposure.
  • the deterioration of biological functions and ability to manage metabolic stress is one of the major consequences of the ageing process.
  • Ageing is a complex, progressive process which also leads to functional and aesthetic changes in the skin.
  • Photoageing is a process of ageing of the skin attributed to continuous, long-term exposure of skin to ultraviolet (UV) radiation of approximately 245-290nm, which may be from natural or synthetic light. Photoageing is thus also known as ageing of the skin, particularly of the face, ears, neck and hands, caused by UVA and UVB rays.
  • UV radiation ultraviolet
  • Dry and/or scaling skin is one of the most common signs of ageing skin. Although certain individuals are more susceptible to dry and/or scaling skin, the appearance of dry and/or scaling skin can affect anyone, regardless of age, gender, or skin type.
  • Dry skin occurs when the skin's outer layer (the stratum corneum with the stratum lucidum) is depleted of water, i.e. via trans-epidermal water loss (TEWL).
  • TEWL trans-epidermal water loss
  • this layer When this layer is well-moistened, it minimizes water loss through the skin and helps keep out irritants, allergens, and germs.
  • stratum corneum dries out, its protective function is reduced. This allows greater water loss, leaving skin vulnerable to environmental factors.
  • the stratum corneum has a water content of 10% to 30%. This water imparts to the skin its soft, smooth, and flexible texture, i.e. the characteristics associated with the youthful appearance of skin. The water comes from the atmosphere, the underlying layers of skin, and sweat. Oil produced by skin glands and fatty substances produced by skin cells act as natural moisturizers, allowing the stratum corneum to seal in water.
  • the body continuously loses water from the skin's surface by evaporation (TEWL). Under normal conditions, the rate of loss is slow, and the water is adequately replaced. Characteristic signs and symptoms of dry skin occur when the water loss exceeds the water replacement, and the stratum corneum's water content falls below 10%.
  • Moisturizers which improve or eradicate dry and/or scaling skin, thereby improving the cosmetic appearance of skin, are highly desirable. Whilst many moisturizers are known in the art, there remains a need for natural products which are effective yet gentle.
  • Epidermal cells exhibiting a undesired or excessive pigmentation i.e. hyperpigmentation, e.g. liver spots
  • exfoliation may be used to remove epidermal cells that are detrimental to the cosmetic appearance of skin.
  • Exfoliation removes the outer strata of epidermis to reveal the newer skin cells beneath. Exfoliation may be achieved by physical means (i.e. abrasion of the skin) or by chemical means. Chemical exfoliants include scrubs containing salicylic acid, glycolic acid, fruit enzymes, citric acid or malic acid and may be applied in high concentrations by a dermatologist, or in lower concentrations in over-the-counter products. Chemical exfoliation may involve the use of products that contain alpha hydroxy acids (AHAs) or beta hydroxy acids (BHAs), or enzymes that act to loosen the glue-like substances that hold the cells together at cell junctions, allowing them to ease away. This type of exfoliation is recommended for people treating acne.
  • AHAs alpha hydroxy acids
  • BHAs beta hydroxy acids
  • a composition comprising molecules, namely polypeptides or portions of polypeptides, which are found in fish hatching fluid have surprisingly now been found to be remarkably effective at improving the cosmetic appearance of skin, particularly reducing the physical signs or symptoms associated with ageing skin.
  • Oocytes of all vertebrates have characteristic extracellular envelopes, known as vitelline envelopes, eggshells or chorion (used interchangeably herein), which are made up by the cross-linkage of various polypeptides.
  • Proteases with different specificities act on the chorion to soften, erode and/or breakdown (i.e. degrade) the eggshell and facilitate the release of the embryo.
  • fluid released from the egg during the hatching process and/or the fluid in which the embryo hatches comprises a multitude of polypeptides and portions of polypeptides, i.e. degradation products.
  • Haching fluid enzymes have already been isolated and used in cosmetic applications on the skin ( WO2011/064384 , WO2010/049688 ).
  • Compositions comprising proteins and portions of polypeptides, which are derived from Salmonidae hatching fluid have surprisingly been found to have pronounced effects on the cosmetic appearance of skin ( Wo2012/175742 , Wo2012/175743 ).
  • compositions comprising Salmonidae hatching fluid polypeptides and portions of polypeptides are capable of restoring the youthful appearance of skin.
  • Hatching fluid from other fish contains polypeptides that are functionally equivalent to the polypeptides found in hatching fluid from Salmonidae.
  • the combination of polypeptides and portions of polypeptides in the compositions defined herein (which are thought to comprise at least 50 different polypeptides or portions of polypeptides) may interact with different types of proteins present in the dermis and epidermis of the skin. It is believed that the combination of polypeptides and portions of polypeptides may work in synergy and that these interactions may be, at least in part, responsible for the effects of the composition on the cosmetic/aesthetic appearance of the skin.
  • the invention can be seen to provide a composition comprising polypeptides and portions of polypeptides derivable from fish hatching fluid, wherein the composition is not obtained or obtainable from Salmonidae hatching fluid.
  • the composition is for use in, or in methods for, promoting the aesthetic appearance of skin.
  • the composition as described herein is for use in, or in methods for, improving the cosmetic appearance of skin.
  • the invention may be seen as providing a composition comprising polypeptides and portions of polypeptides derivable from fish hatching fluid, except Salmonidae hatching fluid, as described herein for use in, or in methods for, restoring the youthful appearance to aged skin and/or combating the signs of ageing skin.
  • the composition referred to above is also referred to herein as a "hatching fluid extract".
  • said extract may comprise native non-proteinaceous material.
  • compositions comprising polypeptides and portions of polypeptides derivable from fish hatching fluid, which is not obtained or obtainable (i.e. derived) from Salmonidae hatching fluid, as described herein may be provided as a cosmetic composition, which comprises one or more pharmaceutically acceptable excipients and/or diluents.
  • the invention is defined by the claims. We describe in one aspect the present invention a method of preparing a cosmetic composition as described herein from fish hatching fluid, wherein said hatching fluid is not Salmonidae hatching fluid, consisting of the steps of:
  • hatching fluid is the fluid released from eggs during the process of hatching and may be in a crude, diluted or filtered form.
  • the crude hatching fluid refers to undiluted, untreated fluid.
  • Diluted hatching fluid refers to hatching fluid which may have been mixed with other fluid during or after hatching.
  • the present invention also provides a cosmetic composition obtained or obtainable by the method as defined in claim 11.
  • the step of exchanging the water in the filtrate may be performed using any suitable method known in the art, e.g. diafiltration or dialysis. In a particularly preferred embodiment, this step is performed using diafiltration using a filter with an exclusion size of less than 15kDa, preferably 10kDa or less, e.g. 9, 8, 7, 6, 5, 4, 3kDa or less.
  • Diafiltration uses ultrafiltration membranes to remove e.g. salts or other unwanted or undesirable microsolutes from a solution or as a way of exchanging the solvent, e.g. buffer, of a solution. Small molecules are separated from a solution while retaining larger molecules in the retentate (the material which does not pass through the filter). Microsolutes and solvents, e.g. water, are generally easily washed through the membrane. Typically about 3 volumes of diafiltration solvent (e.g. phosphate buffered saline) will eliminate 95% of the microsolute.
  • diafiltration solvent e.g. phosphate buffered saline
  • the above filtrate from step (ii) is initially processed by diafiltration and this results in the concentration of the retentate as a proportion of the solution (which contains the soluble impurities/unwanted fraction of the hatching fluid) passes through the membrane.
  • the retentate is then diluted with a pharmaceutically acceptable buffer, e.g. 0.5mM Sodium phosphate and 1mM Sodium chloride, phosphate buffered saline etc.
  • the diluted retentate may be subjected to repeated rounds of diafiltration, if necessary.
  • the retentate is diluted such that the filtrate from step (iv) has an enzymatic activity of 3000-5000mU/L, preferably 3000-4000mU/L and most preferably about 3400mU/L.
  • the enzymatic activity of the filtrate may be measured by the capacity of the filtrate to cleave the Factor Xa chromogenic substrate (CH 3 OCO-D-CHA-Gly-Arg-pNA-AcOH, Sigma aldrich product number: F3301-25MG).
  • the hatching fluid Prior to the step of diafiltration the hatching fluid may comprise an enzymatic activity in the range of 10 to 150,000mU/L.
  • One unit (1U) may be defined as the amount of the enzyme required to catalyze the conversion of 1 ⁇ mol of substrate per minute.
  • the Factor Xa chromogenic substrate (Sigma-Aldrich) is cleaved by an enzyme present in the hatching fluid yielding a yellow product that can be measured conveniently using spectrophotometrical analysis at a wavelength of 405 nm.
  • a typical assay comprises the addition of 100 ⁇ l hatching fluid solution, obtainable from step (iii) of the above method, to 600 ⁇ l substrate solution, comprising 10 ⁇ l Factor Xa chromogenic substrate (10 mg/ml in milli-q or distilled water), 70 ⁇ l 0.2 M Tris-HCI pH 8.5 and 520 ⁇ l dH 2 O.
  • the change in absorbance may be measured for 5-20 minutes (or up to an hour for samples with low enzymatic activity), typically 10 minutes.
  • the result is multiplied with an appropriate factor, e.g. 10 (for a 10 minute assay) to get the enzyme activity per 1 ml of sample.
  • an appropriate factor e.g. 10 (for a 10 minute assay) to get the enzyme activity per 1 ml of sample.
  • Other appropriate and equivalent substrates may be used to determine the activity of the hatching fluid.
  • Synchronized hatching may be achieved by any suitable method known in the art. For instance, some eggs may be synchronized using photo-manipulation, e.g. transferring eggs from the light (which inhibits hatching) in to conditions with no light. Manipulation of the temperature of the eggs, e.g. the temperature of the solution in which the eggs hatch, deoxygenation of the hatching environment, e.g. deoxygenation of the solution in which the eggs hatch ( Oppen-Berntsen et al.
  • synchronized hatching may be achieved using pheromones, e.g. peptide pheromones capable of affecting, i.e. stimulating, embryo development and hatching.
  • the eggs may be suspended in a minimal volume of water, which may be equivalent to the volume of eggs or less, e.g. for every 1ml of eggs a suspending liquid of ⁇ 1, 0.75, 0.5, 0.25 ml may be used, e.g. from 0.5 to 1ml.
  • synchronized, rapid hatching of said eggs is such that hatching is complete within less than 6 hours for more than 80% of the embryos. In particularly preferred embodiments, hatching is complete within less than 5, 4, 3 or 2 hours, such as 0.5-6 hours, 1-5 hours, 1.5-4 hours, 2-3 hours, e.g. 1-2 hours. Furthermore, in some embodiments hatching is complete within the periods stated above for more than 85%, 90%, or 95% of the embryos, e.g. more than 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% of the embryos. It may be advantageous to dilute the hatching fluid to facilitate the subsequent purification steps, e.g. to reduce the viscosity of the hatching fluid.
  • the method may comprise a further step of diluting the hatching fluid prior to step (d).
  • the filtrate may be diluted by a factor of at least 0.1, 0.2, 0.5, 0.75, 1.0, 1.5, 2, 3, 4, 5, 10, 15, 20, 50, 100, 1000, 5000 or 10000.
  • the method of preparing a cosmetic composition described above results in an enriched preparation which is preferably substantially free of any contaminating components derived from the source material or material used in the isolation procedure, e.g. components other than the polypeptides or portions of polypeptides comprised in the crude hatching fluid.
  • the composition may be enriched to a degree of purity of more than 30, 40, 50 or 60%, e.g. >70, 80 or 90%, purity as assessed w/w (dry weight) of the polypeptides and portions of polypeptides in comparison to the starting hatching fluid, i.e. 90% purity refers to a loss of 90% of the starting material (contaminating components) through the course of the method of preparation.
  • compositions may be used which have lower purity, e.g. retain more than 40, 50, 60, 70, 80 or 90% of the starting material.
  • the filtrate may itself form the cosmetic composition
  • the product (the filtrate of step (iv)) obtained or obtainable from the above method may be diluted (or concentrated) to an appropriate concentration to produce the cosmetic composition and/or prior to its use in the methods and uses of the invention in step (v).
  • the method may comprise a further step of diluting (or concentrating) the composition.
  • the filtrate may be diluted (or concentrated) by a factor of at least 1.5, 2, 3, 4, 5, 10, 15, 20, 50, 100, 1000, 5000 or 10000.
  • the final composition comprises 0.5-10%, e.g. 0.5-5%, preferably 0.5-3% (e.g. 1 or 3%) of the filtrate of step (iv).
  • the solution from step (iii) of the above method is diluted or concentrated to achieve a solution with an enzymatic activity of 1000-10000mU/L as measured by the above described method.
  • the solution, and therefore the filtrate from step (iv) comprises an activity of 2000-10000, 3000-9000, 3000-7000, 3000-6000, 3000-5000 or 3000-4000mU/L.
  • the solution comprises an activity of about 3400mU/L.
  • one or more pharmaceutically acceptable excipients and/or diluents may be added to the product obtained or obtainable from the above method.
  • the method may comprise a further step of adding one or more pharmaceutically acceptable excipients and/or diluents to the composition or combining the composition with one or more pharmaceutically acceptable excipients and/or diluents during step (v).
  • Alternative or additional preparation method steps include changing or modifying the solvent, e.g. pH, ion concentration etc.
  • compositions or combining the composition with one or more pharmaceutically acceptable active components may include minerals, vitamins, enzymes, proteins, peptides, amino acids, lipids, antioxidants, polysaccharides, substances suitable as sunscreen filters, chemical exfoliants, extracts and mixtures thereof, as described in more detail below.
  • the cosmetic composition obtained or obtainable from the above methods is suitable for use in the methods of the invention, as described elsewhere herein.
  • the cosmetic composition is for use in improving the cosmetic appearance of skin in a mammalian animal.
  • the invention also provides a method for improving the cosmetic appearance of skin of a mammalian animal wherein a cosmetic composition as defined above is administered to said animal.
  • a further aspect of the invention is the use of a cosmetic composition as defined above in the manufacture of a medicament for improving the cosmetic appearance of skin of a mammalian animal.
  • Polypeptides as referred to herein are molecules with preferably more than 50, 100, 150, 200 or 250 residues and/or less than 500, 400, 300, 200 or 100 residues or a range selected therefrom.
  • a "portion" preferably comprises at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or more amino acids of the sequence from which it is derived. Said portion may be obtained from a central or N-terminal or C-terminal portions of the sequence.
  • compositions as defined herein may be obtained from any fish eggs except Salmonidae eggs, i.e. the compositions of the present invention are not obtained or obtainable from Salmonidae eggs, e.g. eggs from the sub-families Salmo and Oncorhynchus, such as Atlantic salmon ( Salmo salar ) or Pacific salmon ( Oncorhynchus masou ) .
  • Salmonidae eggs e.g. eggs from the sub-families Salmo and Oncorhynchus, such as Atlantic salmon ( Salmo salar ) or Pacific salmon ( Oncorhynchus masou .
  • fish lay eggs which undergo little or no other embryonic development within the mother and fish eggs therefore represent a useful source of hatching fluid from which the cosmetic composition of the invention may be obtained or obtainable by the method described herein.
  • suitable fish that may provide eggs as the starting material for the methods of the invention include any fish of the Teleostei infraclass, which is one of three infraclasses of the class Actinopterygii, except fish from the Salmondiae family.
  • the fish may be selected from a fish of any Superorder selected from the list consisting of Osteoglossomorpha, Elopomorpha, Clupeomorpha, Ostariophysi, Protacanthopterygii (excluding fish from the Salmonidae family), Stenopterygii, Cyclosquamata, Scopelomorpha, Lampridiomorpha, Polymyxiomorpha, Paracanthopterygii and Acanthopterygii.
  • the fish may be selected from a fish of any Order selected from the list consisting of Osteoglossiformes, Hiodontiformes, Elopiformes, Albuliformes, Notacanthiformes, Anguilliformes, Saccopharyngiformes, Clupeiformes, Gonorynchiformes, Cypriniformes, Characiformes, Gymnotiformes, Siluriformes, Argentiniformes, Salmoniformes (excluding fish from the Salmonidae family), Esociformes, Osmeriformes, Ateleopodiformes, Stomiiformes, Aulopiformes, Myctophiformes, Lampriformes, Polymixiiformes, Percopsiformes, Batrachoidiformes, Lophiiformes, Gadiformes, Ophidiiformes, Mugiliforme
  • the fish may be selected from a fish of any Order selected from the list consisting of Salmoniformes (excluding fish from the Salmonidae family), Cypriniformes, Perciformes, Siluriformes, Mugiliformes and Acipenseriformes.
  • the fish may be selected from a fish of any Family selected from the list consisting of Cyprinidae, Cichlidae, Pangasiidae, Sciaenidae, Serranidae, Carangidae, Sparidae, Lateolabracidae, Moronidae, Mugilidae, Oryziinae, Latidae, Eleotridae and Acipenseridae.
  • Family selected from the list consisting of Cyprinidae, Cichlidae, Pangasiidae, Sciaenidae, Serranidae, Carangidae, Sparidae, Lateolabracidae, Moronidae, Mugilidae, Oryziinae, Latidae, Eleotridae and Acipenseridae.
  • the fish may be a bony-tongued fish, a mooneye, a goldeye, a ladyfish, a tarpon, a bonefish, a halosaur, a spiny eel, a true eel, a gulper, a gulper eel, a herring, an anchovy, a milkfish, a barb, a carp, a danio, a goldfish, a loach, a minnow, a rasbora, a characin, a pencilfish, a hatchetfish, a piranha, a tetra, an electric eel, a knifefish, a catfish, a barreleye, a slickhead, a pike, a smelt, a galaxiid, a jellynose fish, a bristlemouth, a marine hatchetfish, a Bombay duck fish,
  • the fish may be any species selected from Grass carp ( Ctenopharyngodon idella ) , Silver carp ( Hypophthalmichthys molitrix ) , Catla (Catla catla), Common carp ( Cyprinus carpio ) , Bighead carp ( Hypophthalmichthys nobilis ) , Crucian carp ( Carassius carassius ) , Nile tilapia ( Oreochromis niloticus niloticus ) , Pangas catfish ( Pangasius pangasius ) , Roho labeo ( Labeo rohita ) , Large yellow croaker ( Larimichthys crocea ) , Greasy grouper ( Epinephelus tauvina ) , Japanese amberjack ( Seriola quinqueradiata ) , Gilthead seabream ( Sparus aurata ) , Japanese seabass ( Lateolabrax japonic
  • the cosmetic compositions may be obtained from hatching fluid from more than one type of egg, i.e. eggs from more than one type of fish.
  • the hatching fluid from two or more types of egg could be used in the method described herein to obtain the cosmetic composition of the invention.
  • the method of the invention may include a step of combining the hatching fluid collected from the hatched eggs of one or more fish, e.g. before or after filtration.
  • the eggs from the fish described herein may be viewed as natural biological variations of the starting material.
  • compositions described herein are for use in vivo as discussed herein.
  • pharmaceutically acceptable or “physiologically acceptable” or “cosmetically acceptable” is meant that the ingredient must be suitable for cosmetic application and compositions. The ingredients also must be compatible with other ingredients in the composition as well as physiologically acceptable to the recipient.
  • the active ingredient i.e. the composition obtainable by the method described above, for administration may be appropriately modified for use in a cosmetic composition.
  • the composition used in accordance with the invention may be stabilized against degradation for example by the use of appropriate additives such as salts or non-electrolytes, acetate, SDS, EDTA, citrate or acetate buffers, mannitol, glycine, HSA or polysorbate.
  • compositions obtained by the methods described herein may be present in the compositions for the cosmetic uses as the sole active ingredient or may be combined with other ingredients, particularly other active ingredients, e.g. to augment the cosmetic effect (as described above) or to make the composition more appealing to the consumer.
  • compositions obtained by the methods of the invention that are derived from different sources of hatching fluid may be combined.
  • compositions described herein exhibit properties that are useful in improving the cosmetic appearance of skin, particularly of aged skin, e.g. photo-aged skin.
  • composition described herein may also comprise impurities, e.g. after the preparation of said composition from one of the above described natural sources.
  • the various polypeptides or portions of polypeptides derivable from fish hatching fluid may be present (in combination) in the range 0.0001 to 50% w/w of the cosmetic composition prepared according to the above described method.
  • said polypeptides or portions of polypeptides derivable from fish hatching fluid are present (in combination) at a range of 0.0001 to 10% w/w of the cosmetic composition (or up to 10-40%), e.g.
  • individual polypeptides or portions of polypeptides derivable from fish hatching fluid may be present at the range of 1x10 -6 to 10% w/w of the cosmetic composition.
  • said individual polypeptides or portions of polypeptides derivable from fish hatching fluid may be present at the range 1x10 -6 to 5% w/w of the cosmetic composition, e.g.
  • the proportion of the polypeptides or portions of polypeptides derivable from fish hatching fluid in the cosmetic compositions may be defined relative to the other solutes in the composition, i.e. excluding solvents, e.g. water.
  • said polypeptides or portions of polypeptides, in combination may be present at the range of 1-100% w/w of the dry mass of the composition.
  • the polypeptides or portions of polypeptides, in combination may be present at the range of 1-90% w/w of the dry mass of the composition, e.g. 5-80%, 10-70%, 20-60%, 30-50% w/w of the dry mass of the composition.
  • polypeptides or portions of polypeptides in combination, may be present at the range of 1-40%, 2-39%, 3-38%, 4-37% etc. w/w of the dry mass of the composition.
  • individual polypeptides or portions of polypeptides may be present at the range of 0.0001 to 50% w/w of the dry mass of the composition, e.g. 0.0001 to 40%, 0.001 to 30%, 0.01 to 25% w/w of the dry mass of the composition.
  • the composition may be diluted for use according to the invention in step (v).
  • the invention is directed to methods for improving the cosmetic appearance of skin, this may include the treatment of a disorder, abnormality or condition, but in all cases the treatment is cosmetic in nature.
  • cosmetic is intended to refer to a treatment which does not cure, treat or prevent a disease or disorder, but instead serves as a skincare product or to modify or improve the appearance of the skin, e.g. the colour, texture or moisture content of the skin.
  • the invention thus provides a cosmetic method of improving the appearance of skin of a mammalian animal, wherein a cosmetic composition as described hereinbefore is administered to said animal.
  • the skin is aged skin.
  • “Aged skin” refers to skin that displays one or more signs or symptoms of ageing, i.e. the appearance of wrinkles, fine lines, hyperpigmentation, laxity (sagging), dry skin, scaling or transepidermal water loss (TEWL).
  • "aged skin” is determined relative to normal optimum skin, i.e. healthy, hydrated, normally pigmented and non-aged skin. In this respect, aged skin need not be related to the age of the subject and may be aged prematurely, e.g. by chronic exposure to sunlight (photo-damage).
  • the relative parameters for "normal optimum skin” may be determined as the average measurements of the above signs of ageing from a number of subjects of the same or similar age to the subject in question, e.g.
  • the relative parameters for "normal optimum skin” may be taken as the measurements from subjects that are younger than the subject in question.
  • the composition described herein may be used to restore the youthful appearance of skin, relative to the skin of the subject at an earlier age.
  • the invention provides a cosmetic composition as described hereinbefore for use in the treatment of dermatoheliosis in a mammalian animal, preferably wherein said cosmetic composition is for administration to the skin of said animal.
  • said composition is for topical administration.
  • improving the cosmetic appearance of skin involves a reduction or prevention in the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal water loss.
  • wrinkles e.g. aged or photo-damaged skin
  • fine lines e.g. wrinkles are reduced.
  • Reduction or prevention in the cosmetic appearance or prevalence of the signs or symptoms of e.g. aged skin or dermatoheliosis may mean that there is a reduction in the number and/or severity of the sign or symptom. For instance, the number of fine lines and wrinkles may be reduced and/or the size, e.g. the depth, of the wrinkles or fine lines may be reduced or minimized. Furthermore, reduction or prevention may involve stopping, or reducing the rate of, the appearance of new signs or symptoms.
  • Dry skin refers to an epidermis that lacks moisture or sebum, often characterized by a pattern of fine lines, scaling, and an itching and/or burning feeling. Dry skin can occur as a skin condition in itself (e.g. due to age) or may be the symptom of a skin disorder or condition such as sun-damage.
  • the reduction of dry skin, scaling, fine-lines or transepidermal water loss may be achieved by the moisturizing effects of the composition described above.
  • the invention may be seen to provide a cosmetic method of moisturizing skin of a mammalian animal, wherein a cosmetic composition as defined herein is administered to said animal.
  • the present invention provides a cosmetic composition as described herein for use in moisturizing skin of a mammalian animal.
  • the composition may alternatively be used to prepare a cosmetic medicament for that purpose.
  • “Moisturizing” as referred to herein covers moisturizers which prevent loss of water from the skin (e.g. TEWL) as well as moisturizers (humectants) that attract and retain water when applied to the skin and emollients (which improve defective desquamation).
  • the skin is the skin of the face, ears, neck, hands or scalp.
  • “Wrinkles” are folds, ridges or creases in the skin. Skin wrinkles typically appear as a result of ageing processes.
  • the dermis comprises many of the structural elements of skin, which include collagen, which gives the skin its strength, glycosaminoglycans which give the skin its turgor, and elastin fibres which give the skin its elasticity or spring.
  • the dermal layer gets thinner and the skin also produces less collagen.
  • the elastin fibres that provide elasticity wear out. These changes in the scaffolding of the skin cause the skin to wrinkle and sag.
  • the rete-ridges of the dermal-epidermal junction flatten out, making the skin more fragile and making it easier for the skin to shear. This process also decreases the amount of nutrients available to the epidermis by decreasing the surface area in contact with the dermis, also interfering with the skin's normal repair process.
  • the fat cells In the subcutaneous layer the fat cells get smaller with age. This leads to more noticeable wrinkles and sagging (laxity), as the fat cells cannot "fill in” the damage from the other layers.
  • UVA and UVB radiation i.e. sunlight
  • UVA and UVB radiation causes collagen to break down at a higher rate than with just chronologic ageing.
  • Sunlight damages collagen fibres and causes the accumulation of abnormal elastin.
  • matrix metalloproteinases MMP
  • metalloproteinases remodel sun-injured skin by manufacturing and reforming collagen.
  • this process does not always work well and some of the metalloproteinases actually break down collagen. This results in the formation of disorganized collagen fibres known as solar scars.
  • the repetition of this imperfect rebuilding/regeneration process causes wrinkles to develop and skin laxity.
  • the skin condition to be treated or prevented cosmetically is a pigmentation condition, disorder or abnormality.
  • Pigmentation disorders or abnormalities of the skin may occur as a result of age or may result from premature ageing due to e.g. sun damage. Altered pigmentation may result from a local excess of melanocytes or increases in melanocyte activity, or both. Pigmentation disorders include liver, sun or age spots (solar lentigo) and other blemishes such as freckles.
  • one or more of the signs or symptoms of ageing may be measured as described in the Examples and compared to the same signs of skin that is chronologically or physiologically younger, preferably when an improvement is the reduction in one or more of the signs or symptoms of ageing.
  • the cosmetic uses are achieved by topical administration to the skin.
  • treating refers to the reduction, alleviation or elimination, preferably to normal levels, of one or more of the cosmetic symptoms or effects of said condition or disorder e.g. presence or extent of dry skin, extent or area of pigmentation etc. relative to the symptoms or effects present on a different part of the body of said individual where the skin does not suffer from said condition or disorder and not subject to said treatment or in a corresponding normal individual not subject to said treatment.
  • Preventing refers to absolute prevention, or reduction or alleviation of the extent or timing (e.g. delaying) of the onset of that symptom or effect.
  • conditions typified by dry, abnormally pigmented, wrinkled skin may be prevented by regular application of cosmetic compositions described herein before the appearance of such a condition.
  • cosmetic methods of treatment or prevention according to the invention may advantageously be combined with administration of one or more active ingredients which are effective in treating or preventing the disorders or conditions and/or to achieve, e.g. moisturization.
  • cosmetic compositions described herein may additionally contain one or more of such active ingredients.
  • compositions as herein defined and optionally one or more additional active ingredients as a combined preparation for simultaneous, separate or sequential use in human or mammalian animal therapy, as described herein.
  • compositions described herein may be formulated in a conventional manner with one or more physiologically acceptable carriers, excipients and/or diluents, according to techniques well known in the art using readily available ingredients.
  • the compositions may be provided as water based, glycerin based, alcohol (up to 20%) based, acrylate based oil/water emulsions, xanthan gum based oil/water emulsions or water/oil emulsions, for example, at pH 3.5-11, preferably pH 5.5-9.
  • compositions may be incorporated, optionally together with other active substances as a combined preparation, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations such as powders, sachets, cachets, elixirs, suspensions (infusion fluids), emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, sterile packaged powders, and the like.
  • the compositions may be stabilized by use of freeze-drying, undercooling or Permazyme. Such compositions form compositions of the invention (i.e. are prepared in accordance with step (v)).
  • Suitable excipients, carriers or diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, calcium carbonate, calcium lactose, corn starch, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable mixtures thereof.
  • Agents for obtaining sustained release formulations such as carboxypolymethylene, carboxymethyl cellulose, cellulose acetate phthalate, or polyvinylacetate may also be used.
  • compositions may additionally include lubricating agents, wetting agents, emulsifying agents, viscosity increasing agents, granulating agents, disintegrating agents, binding agents, osmotic active agents, suspending agents, preserving agents, sweetening agents, flavouring agents, adsorption enhancers (e.g. surface penetrating agents, e.g.
  • bile salts bile salts, lecithins, surfactants, fatty acids, chelators
  • browning agents organic solvent, antioxidant, stabilizing agents, emollients, silicone, alpha-hydroxy acid, demulcent, anti-foaming agent, moisturizing agent, vitamin, fragrance, ionic or non-ionic thickeners, surfactants, filler, ionic or non-ionic thickener, sequestrant, polymer, propellant, alkalinizing or acidifying agent, opacifier, colouring agents and fatty compounds and the like.
  • active ingredients or components in the cosmetic composition may be selected from any one or more of minerals, vitamins, enzymes, proteins, peptides, amino acids, lipids, polysaccharides, substances suitable as sunscreen filters, chemical exfoliants, extracts, skin-conditioning agents, antioxidants and mixtures thereof.
  • proteins examples include collagen and/or a derivative thereof (e.g. portions thereof as defined above), a protein or peptide which is capable of promoting cell growth, glycoprotein 1, glycoprotein 2 and laminin.
  • composition of the invention may be provided with enzymes including, but not limited to, any one or more of, fruit enzymes (e.g. bromelain), superoxide dismutase, peroxidase, hyaluronidase and mucopolysaccharidase.
  • fruit enzymes e.g. bromelain
  • superoxide dismutase e.g. bromelain
  • peroxidase e.g. bromelain
  • hyaluronidase e.g. hyaluronidase
  • mucopolysaccharidase e.g., mucopolysaccharidase.
  • Peptides may be selected from, but are not limited to, any one or more of D,L-carnosine, D-carnosine, L-carnosine, anserine and Matrixyl (pentapetide derivative).
  • Amino acids may be selected from, but are not limited to, any one or more of L-alanine, L-arginine, L- asparagine, L-aspartic acid, L-cysteine, L-cystine, glycine, L-glutamine, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine and derivatives thereof including non-naturally occurring amino acids as defined in Table 1.
  • Particularly preferred amino acids as antioxidants may be selected from any one or more of glycine, lysine, arginine, cysteine, cystine, histidine, tyrosine and tryptophan.
  • TABLE 1 Non-conventional amino acid Code
  • Non-conventional amino acid Code ⁇ -aminobutyric acid Abu L-N-methylalanine Nmala ⁇ -amino- ⁇ -methylbutyrate Mgabu L-N-methylarginine Nmarg aminocyclopropane-carboxylate Cpro L-N-methylasparagine Nmasn L-N-methylaspartic acid Nmasp aminoisobutyric acid Aib L-N-methylcysteine Nmcys aminonorbornyl-carboxylate Norb L-N-methylglutamine Nmgln L-N-methylglutamic acid Nmglu cyclohexylalanine Chexa L-N-methylhistidine Nmhis cyclopent
  • the cosmetic composition may comprise one or more lipids which includes fats, oils, waxes and the like.
  • Suitable polar oils are, for example, those from the group of lecithins and fatty acid triglycerides, namely the triglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids with a chain length of from 8 to 24, in particular 12 to 18, carbon atoms.
  • the fatty acid triglycerides can, for example, be chosen advantageously from the group of synthetic, semisynthetic and natural oils, such as, for example, olive oil, sunflower oil, soya oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, thistle oil, evening primrose oil, macadamia nut oil and the like.
  • synthetic, semisynthetic and natural oils such as, for example, olive oil, sunflower oil, soya oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, thistle oil, evening primrose oil, macadamia nut oil and the like.
  • the oil may be selected from volatile oils, non-volatile oils or mixtures thereof.
  • Non-volatile oils include oils that fulfill at least one of the following definitions: (a) the oil exhibits a vapour pressure of no more than 0.2mm Hg at 25°C and one atmosphere pressure; (b) the oil has a boiling point at one atmosphere of at least 300°C.
  • Volatile oils include materials that are not "non-volatile" as defined above.
  • Non-volatile oils may be selected from non-volatile silicone oils, non-volatile hydrocarbon oils and mixtures thereof.
  • Suitable non-volatile silicone oils include linear polymethylsiloxanes and, preferably, non-volatile silicone oils are high molecular weight dimethicones. Examples of commercially available linear polymethylsiloxanes include DC 200 Fluid 20Cst, DC 200 Fluid 100Cst, DC 200 Fluid 350Cst from Dow Corning Corporation.
  • Suitable non-volatile hydrocarbon oils include branched esters of diglycerin or triglycerin or the esters or 1,2,3,4 butane triol or erythritol, di erythritol or tri erthyritol.
  • non-volatile hydrocarbon oils comprise erythrityl triethylhexanoate (available as Salacos E-38 from Nisshin Oilio) and Polyglyceryl-2 triisostearate (available as Cosmol 43V from Nisshin Oilio), diethyl hexyl carbonate (available as Tegosoft DEC from Degussa), dicapryl Ether (available as Cetiol OE from Cognis AG), dicapryl Carbonate (available as Cetiol CC from Cognis AG), isononyl isononanoate (available as Lanol 99 from Seppic), tridecyl Neopentanoate (supplied as Ceraphyl 55 from International Speciality Products), or a mixture thereof.
  • erythrityl triethylhexanoate available as Salacos E-38 from Nisshin Oilio
  • Polyglyceryl-2 triisostearate available as Cosmol 43V from Nisshin Oilio
  • Volatile oils may be selected from volatile silicone oils, both functionalised and non-functionalised, volatile hydrocarbon oils and mixtures thereof. Volatile oil useful in the present invention may be saturated or unsaturated, have a straight or branched chain or a cyclic structure or have any one or more of these features.
  • volatile hydrocarbons oils examples include polydecanes such as isododecane and isodecane (e.g., Permethyl-99A which is available from Presperse Inc.) and the C7-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals).
  • polydecanes such as isododecane and isodecane (e.g., Permethyl-99A which is available from Presperse Inc.) and the C7-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals).
  • the volatile silicone oil may be selected from cyclopentasiloxane, cyclohexasiloxane or a mixture thereof.
  • Examples of commercially available volatile cyclic silicone oils include DC 244, DC 245, DC 344, and DC 345 from Dow Corning Corp.; SF-1204 and SF-1202 Silicone Fluids from Momentive Performance Materials; GE 7207 and 7158 from General Electric Co.); and, SWS-03314 from SWS Silicones Corp.
  • the linear volatile silicone oil may be a linear polymethylsiloxane.
  • An example of commercially available linear polymethylsiloxanes includes DC 200 Fluid, 5Cst from Dow Corning Corp.
  • the cosmetic composition of the invention may further comprise one or more polysaccharides selected from, but not limited to, any one or more of anionic polysaccharides (e.g. alginic acid, pectin, xanthan gum, hyaluronic acid, chondroitin sulfate, gum arabic, gum karaya, gum tragacanth, carboxymethyl-chitin, cellulose gum, glycosaminoglycans), cationic polysaccharides (e.g. chitosan, acetylated chitosan, cationic guar gum, cationic hydroxyethylcellulose (HEC)), nonionic polysaccharides (e.g.
  • anionic polysaccharides e.g. alginic acid, pectin, xanthan gum, hyaluronic acid, chondroitin sulfate, gum arabic, gum karaya, gum tragacanth, carboxymethyl-chi
  • starch dextrins, guar gum, cellulose ethers such as hydroxyethylcellulose, methylcellulose and nitrocellulose
  • amphoteric polysaccharides e.g. carboxymethylchitosan, N-hydroxy-dicarboxyethyl-chitosan, modified potato starch
  • hydrophobic polysaccharides e.g. cetyl hydroxyethylcellulose, polyquaternium24
  • the cosmetic composition may further comprise a substance suitable as a sunscreen filter such as an organic sunscreen, e.g. a cinnamic derivative.
  • a sunscreen filter such as an organic sunscreen, e.g. a cinnamic derivative.
  • the organic sunscreen active may be selected from hydrophilic organic sunscreen, hydrophobic organic sunscreen, or mixtures thereof. Suitable examples of sunscreens may be found in the CTFA International Cosmetic Ingredient Dictionary and Handbook, 7th edition volume 2, pp.1672, edited by Wenning and Mc Ewen (The Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D.C. 1997 ).
  • the organic sunscreen may be selected from alkyl ⁇ , ⁇ -diphenylacrylate derivatives, ⁇ -cyano ⁇ , ⁇ -diphenylacrylate derivatives, anthranilate derivatives, benzophenone derivatives, camphor derivatives, dibenzoylmethane derivatives, p-aminobenzoic derivatives, salicylic derivatives, triazine derivatives, or mixtures thereof.
  • the hydrophobic organic sunscreen may be selected from 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethane; 4-isopropyldibenzoylmethane; 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethane, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, or a mixture thereof.
  • An example of commercially available 4-isoproplydibenzoylmethane, also known as isopropyldibenzoylmethane includes Eusolex TM 8020 from Merck & Co., Inc.
  • Examples of commercially available 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, also known as Octocrylene, include Uvinul N539 SG from BASF; and Eusolex OCR from Rona/Merck.
  • the hydrophilic organic sunscreen may be 2-phenylbenzimidaole-5-sulfonic acid.
  • 2-phenylbenzimidaole-5-sulfonic acid also known as PBSA, includes Eusolex 232 from Rona/Merck.
  • cinnamic derivative sunscreens may be found in the CTFA International Cosmetic Ingredient Dictionary and Handbook, 7th edition volume 2, pp.1672, edited by Wenning and Mc Ewen (The Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D.C. 1997 ).
  • the cinnamic derivative may be selected from 2-ethylhexyl-p-methoxycinnamate, diethanolamine methoxycinnamate, 2-ethoxyethyl-p-methoxycinnamate, or a mixture thereof.
  • the cinnamic derivative may be 2-ethylhexyl-p-methoxycinnamate.
  • the cosmetic composition may contain a chemical exfoliant selected from, but not limited to, any one more of alpha hydroxy acids (AHAs), beta hydroxy acids (BHAs) or poly-hydroxy acids, such as salicylic acid, glycolic acid, citric acid and malic acid.
  • AHAs alpha hydroxy acids
  • BHAs beta hydroxy acids
  • poly-hydroxy acids such as salicylic acid, glycolic acid, citric acid and malic acid.
  • Extracts that may be incorporated in the cosmetic composition include, but are not limited to plant extracts, which may comprise phenolic compounds such as, for example, flavonoids (e.g., glycosyl rutin, ferulic acid, caffeic acid), furfurylidene glucitol, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic resin acid, nordihydroguaiaretic acid, trihydroxybutyrophenone and derivatives thereof.
  • plant extracts for use in the composition of the invention include aloe vera extract, ginseng extract and horsetail extract.
  • Ginseng extract is obtainable by extracting with a hydrophilic solvent (in particular, water, ethanol, glycol, or any mixtures thereof) the root of Panax ginseng.
  • the extract contains saponins, sterols, carbohydrates, pectin, vitamins, minerals and lipids.
  • Horsetail extract is obtainable by extracting with a hydrophilic solvent (e.g., water, ethanol, glycol, or any mixtures thereof) the whole herb of Equisetum arvense.
  • the extract contains silicates, flavinoids, saponosides, caffeic acid and ferulic acid.
  • the cosmetic composition may further comprise a skin-conditioning agent.
  • the skin-conditioning agent may be selected from humectants, exfoliants, emollients or mixtures thereof.
  • Humectants includes polyhydric alcohols such as glycerine, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexanetriol, ethoxylated glycerin, propoxylated glycerine or mixtures thereof.
  • antioxidants examples include but are not limited to amino acids, vitamins, minerals, carotenoids, peptides, thiols, sulfoximine compounds, chelators, unsaturated fatty acids, phenolic compounds, plant extracts, stilbenes, uric acid, mannose, chlorogenic acid, imidazoles (e.g. urocanic acid), furfurylidenesorbitol, ubiquinone, ubiquinol, plastoquinone, phytosterols and derivatives thereof (e.g. salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and/or lipid derivatives), some of which are described above.
  • Vitamins may be selected from, but are not limited to, any one or more of vitamin A and derivatives thereof (e.g. retinoid or retinol or their derivatives such as retinyl palmitate or retinyl proprionate), biotin, folic acid, calcium pantothenate, nicotinamide, pyridoxine HCI, pyridoxal HCI, riboflavin, thiamine HCI, thymidine, vitamin B12, vitamin B3 (e.g. niacinamide), vitamin B5 (e.g. panthenol), vitamin C and derivatives thereof (e.g., ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate).
  • vitamin A and derivatives thereof e.g. retinoid or retinol or their derivatives such as retinyl palmitate or retinyl proprionate
  • Minerals may be selected from, but are not limited to, any one or more salts of molybdenate (e.g. (NH 4 )OMo 7 O 24 ) aluminium (e.g. AlCl 3 ), calcium (e.g. CaCl 2 ), cobalt (e.g. CoCl 2 ), chromium (e.g. CrK(SO 4 )), copper (e.g. CuSO 4 ), iron (e.g. Fe(NO 3 ) 3 , FeSO 4 ), potassium (e.g. KCI), magnesium (e.g. MgCl 2 ), manganese (e.g. MnCl 2 , MnSO 4 ), phosphate (e.g.
  • molybdenate e.g. (NH 4 )OMo 7 O 24
  • aluminium e.g. AlCl 3
  • calcium e.g. CaCl 2
  • cobalt e.g. CoCl 2
  • chromium e.g. CrK
  • silicate e.g. Na 2 SiO 3
  • sodium e.g. NaCl
  • vanadate e.g. NH 4 VO 3
  • nickel e.g. NiCl 2
  • tin e.g. SnCl 2
  • zinc e.g., ZnO, ZnSO 4
  • selenium e.g.
  • Carotenoids may be selected from, but are not limited to, any one or more of carotenes, e.g. ⁇ -carotene, ⁇ -carotene, ⁇ -lycopene, phytoene etc. and derivatives thereof.
  • Thiols may be selected from, but are not limited to, any one or more of aurothioglucose, propylthiouracil, thioredoxin, lipoic acid, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters and the salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof.
  • Sulfoximine compounds may be selected from, but are not limited to, any one or more of homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, heptathionine sulfoximine, which may be included in the composition such that they are provided in very low dosages (e.g. pmol to ⁇ mol/kg).
  • Chelators may be selected from, but are not limited to, any one or more of apoferritin, desferral, lactoferrin, ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, ⁇ -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof.
  • apoferritin desferral
  • lactoferrin ⁇ -hydroxy fatty acids
  • palmitic acid palmitic acid
  • phytic acid e.g. citric acid, lactic acid, malic acid
  • humic acid e.g. citric acid, lactic acid, malic acid
  • humic acid e.g. citric acid, lactic acid, malic acid
  • humic acid e.g. citric acid, lactic acid, malic acid
  • humic acid e.g. citric acid, lactic
  • Unsaturated fatty acids may be selected from, but are not limited to, any one or more of ⁇ -linolenic acid, linoleic acid, oleic acid and derivatives thereof.
  • Stilbenes and derivatives thereof include, for example, stilbene oxide and trans-stilbene oxide.
  • additional optional active ingredients may be incorporated into the cosmetic compositions of the present invention.
  • additional skin care actives such as farnesol, bisabolol, phytantriol, urea, guanidine (e.g. amino guanidine); hexaminidine compounds, salts or derivatives thereof; sugar amines; self-tanning agents (e.g. dehydroxyacetone); structuring agents; hydrophilic gelling agents; anti-acne medicaments (resorcinol, salicylic acid, and the like); skin soothing and healing agents such as allantoin and the like; and agents suitable for aesthetic purposes such as essential oils, fragrances, skin sensates, opacifiers, aromatic compounds (e.g.
  • compositions described herein may be formulated so as to provide quick, sustained or delayed release of the active ingredients after administration to the body by employing techniques well known in the art.
  • composition may be in any appropriate dosage form to allow delivery or for targeting particular cells or tissues, e.g. as an emulsion or in liposomes, niosomes, microspheres, nanoparticles or the like with which the active ingredient may be absorbed, adsorbed, incorporated or bound. This can effectively convert the product to an insoluble form.
  • These particulate forms may overcome both stability (e.g. degradation) and delivery problems.
  • the active ingredient may be carried in water, a gas, a water-based liquid, an oil, a gel, an emulsion, an oil-in water or water-in-oil emulsion, a dispersion or a mixture thereof.
  • the emulsifier may be selected from nonionic emulsifiers, anionic emulsifiers, cationic emulsifiers, zwitterionic emulsifiers, amphoteric emulsifiers or mixtures thereof.
  • Emulsifiers are known in the art. See, e.g., McCutcheon's, Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation .
  • emulsifiers are preferably selected from polyoxyalkylene copolymers, polyglyceryl copolymers or mixtures thereof.
  • Polyoxyalkylene copolymers also known as silicone polyethers, are described in detail in US 4,268,499 .
  • An example of commercially available polyoxyalkylene copolymers includes DC5225C or DC2-5185C (PEG/PPG-18/18 dimethicone available as blend with cyclopentasiloxane) from Dow Corning Corp.; and, KF6017 or KF6028 (PEG-9 dimethicone) from Shin-Etsu Inc.
  • Examples of commercially available polyglyceryl emulsifiers include KF6100 and KF6104 from Shin-Etsu Inc.
  • compositions are preferably for topical (i.e. to the skin) administration.
  • Topical compositions include gels, creams, ointments, sprays, lotions, salves, sticks, soaps, powders, films, aerosols, drops, foams, solutions, emulsions, suspensions, dispersions e.g. non-ionic vesicle dispersions, milks and any other conventional cosmetic forms in the art.
  • Ointments, gels and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will, in general, also contain one or more emulsifying, dispersing, suspending, thickening or colouring agents.
  • Powders may be formed with the aid of any suitable powder base.
  • Drops and solutions may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing, solubilising or suspending agents. Aerosol sprays are conveniently delivered from pressurised packs, with the use of a suitable propellant.
  • the cosmetic compositions described herein may be topically administered to the skin via a product, device or material to which the polypeptide or composition has been applied, impregnated or chemically bonded.
  • bandages plasters (e.g. adhesive patches), gauze, surgical tape, cotton swabs or other absorbent materials, e.g. a puff, fleece, or sponge, or supportive matrices may be coated, impregnated or chemically bonded with a composition as described herein.
  • many compositions can be applied to the skin using dermal patches that are well described in the art, e.g.
  • the material comprising the composition as described herein may be in the form of a device that can be, e.g. worn by the subject to be treated.
  • the composition as described herein may be applied, impregnated or chemically bonded onto a material or supportive matrix that forms all or part of a diaper, glove, sock etc.
  • the cosmetic compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • a further aspect of the invention comprises the provision of a product, material or device which is coated, impregnated or chemically bonded with a composition as described herein.
  • the invention also extends to such products, materials or devices for uses as described herein.
  • said product is a bandage, plaster (e.g. adhesive patch), gauze, surgical tape or cotton swab or said device is a diaper, glove or sock.
  • compositions described herein may depend upon the source of the composition (i.e. the starting material for the method described above), the mode of administration, the course of treatment, the age and weight of the patient, the cosmetic indication, the body or body area to be treated and may be varied or adjusted according to choice.
  • the composition prepared according to the method of the invention after step (iv) is diluted in step (v) to 0.001, 0.005, 0.01 or 0.1 to 50%, e.g. 0.005-40%, e.g. 0.1 to 25%, such as 0.1 or 0.5 to 5, e.g. 1-5% (w/w or v/v) to provide the final preparation for administration, particularly for topical administration, e.g. a 1% or 3% solution of the composition after step (iv).
  • the additional component may be present in the amounts 0.0001, 0.0005, 0.001 or 0.01 to 50%, e.g. 0.0005-40%, e.g. 0.01 to 25%, such as 0.1 or 0.5 to 5, e.g. 1-5% (w/w of the final preparation for administration, particularly for topical administration).
  • Effective single doses for the composition may lie in the range of from 0.0001-100mg/cm 2 /day (total protein in the composition), e.g. 0.1-100 mg/cm 2 /day, preferably 0.0001-10mg/cm 2 /day, e.g. 0.1-10 mg/cm 2 /day, when applied topically, depending on the mammalian animal being treated, taken as a single dose.
  • liquid solutions Preferably liquid solutions, creams or suspensions would be employed for topical administration.
  • compositions to which the compositions may be applied or administered are limited to mammals.
  • mammals are primates, domestic animals, livestock and laboratory animals.
  • preferred mammalian animals include mice, rats, rabbits, guinea pigs, cats, dogs, monkeys, pigs, cows, goats, sheep and horses.
  • the compositions are applied, or administered, to humans.
  • the composition was prepared from salmon hatching fluid, which is not embraced by the claims.
  • salmon eggs were transferred to minimal volumes of water prior to hatching.
  • Highly synchronous hatching can be induced by elevated (room) temperatures, or by deoxygenation ( Oppen-Berntsen et al. 1990, Aquaculture, 86, pp. 417-430 ), which yields a small volume of highly concentrated preparation of crude polypeptides and portions of polypeptides. Hatching should be complete within 2 hours for more than 95% of the embryos.
  • the hatching fluid was filtered using a standard filter with a 7 ⁇ m pore size, to remove material likely to clog filters in subsequent filtration steps.
  • This filtrate, the processed hatching fluid may be frozen for years without significant degradation, before being thawed and employed for further protein purification. This fact greatly simplifies production of a starting material for purifying the hatching fluid composition.
  • the processed hatching fluid was subjected to filtration using a filter with a 0.45 ⁇ m pore size and the filtrate was collected.
  • the filtrate was then dia-filtrated with a filter exclusion size of 8kDa to exchange water of hatching fluid for buffer.
  • the buffer contained 0.5mM phosphate and 1mM NaCl, although other buffers are equally suitable.
  • phosphate buffered saline or buffers containing millimolar Tris (e.g. 10 mM) at pH around neutrality or slightly alkaline (pH 7.5 - 8.5), containing 5 mM NaCl are suitable.
  • the retentate from the diafiltration step was collected and diluted by the addition of the buffer so that the enzymatic activity of the filtrate, as defined above, was equal to 3400 mU/litre.
  • This filtrate is an enriched preparation of the polypeptides and portions of polypeptides, found in the crude hatching fluid.
  • the hatching fluid composition was prepared as described in Example 1.
  • the composition was prepared as a 1% and 3% skin lotion [v/v] (total volume of composition per unit volume of lotion), the two active skin lotions in the trial, and compared to a control skin lotion which did not comprise the active component, i.e. the hatching fluid composition.
  • the skin lotion was an oil in water (O/W) emulsion.
  • the oil phase represents 9% of the total composition and was emulsified with hydrogenated lecithin.
  • a double blind, placebo controlled clinical trial was conducted to evaluate the effectiveness and tolerance of topical skin treatments in females with mild to moderate photodamaged, i.e. aged, facial skin.
  • the duration of this trial was 12 weeks with visits at baseline, Week 2, Week 6 and Week 12.
  • Efficacy was assessed using visual grading, instrumentation, digital VISIA CR photographs and subject self-assessment questionnaires.
  • Subjects were healthy females ages 40 to 65 and were assigned a three-digit number which, when used in conjunction with the clinical study number, uniquely identified every subject in the study. This number remained with the subject throughout the study to maintain the anonymity of the experiment.
  • the double blind, placebo controlled clinical trial was conducted to evaluate the effectiveness of topical skin treatments in females with mild to moderate photodamaged, i.e. aged, facial skin.
  • the duration of this trial was 12 weeks with visits scheduled at baseline, Week 2, Week 6 and Week 12.
  • Efficacy was assessed using visual grading, instrumentation, digital VISIA CR photographs and subject self-assessment questionnaires.
  • Visit 1 Baseline Visit 2 Week 2 Visit 2 Week 6 Visit 2 Week 12 Informed Consent, eligibility paperwork, facial screening X Right and left side clinical scoring for lines, wrinkles, mottled hyperpigmentation, laxity, clarity and roughness X X X X Right and left side clinical scoring for objective and subjective irritation (erythema, dryness, burning/stinging*, itching*, tight/dry feeling*) *reported by the panelist.
  • X X X X X Right and left side VISIA-CR imaging X X X X Cutometer measurements on the right and left face. X X X X Transepidermal water loss (TEWL) measurements on the right and left face. X X X X X Distribution of test material, vehicle, usage instructions, diary and calendar X Completion of self assessment questionnaires for right and left face. X X X X Diary review and product weighing for compliance X X X X
  • VISIA-CR imaging was taken of the right and left sides of the face. The subjects were imaged such that their hair was pulled back, jewellery was removed, eyes were closed, the subject was centered within the frame and had a neutral facial expression.
  • the Tewameter was used to take a transepidermal water loss (TEWL) measurement at all visits. Measurements were taken on the right and left cheek at the intersection of lines extending down from the corner of the eye and horizontally across the bottom of the nose.
  • TEWL transepidermal water loss
  • the Tewameter measures TEWL utilizing an open chamber system.
  • a hand held probe placed on the skin surface sampled relative humidity at two points above the surface, allowing the rate of water loss to be calculated from the measured humidity gradient.
  • Cutometer was used to assess the viscoelastic properties (i.e. extensibility and elasticity) of the skin.
  • the instrument applies a vacuum to a small area of skin and measures the elastic response of the skin (movement of the skin into and out of the aperture) by an optical technique.
  • Measurements were taken on the right and left cheek at the intersection of lines extending down from the corner of the eye and horizontally across the bottom of the nose, or an alternate location near the jaw.
  • Subjects completed a skin self assessment questionnaire containing questions that describe how the subject perceives their facial skin appearance and condition on the right and left sides of the face.
  • Questionnaires reveal that from 6 weeks of use statistically significant differences were found for mean scores of statements about overall appearance, overall feel, smoothness, softness, clarity and elasticity between the placebo and the cosmetic composition comprising the hatching fluid composition of the invention.
  • In vitro reconstructed human epidermis consists of normal human keratinocytes cultured on an inert polycarbonate filter at the air-liquid interface, in a chemically defined medium. This in vitro model is histologically similar to that of the in vivo human epidermis.
  • FIG. 5 Evalution of scanning electronmicrographs of the treated reconstituted human epidermis after 12 hours ( Figure 5 ) shows that treatment with a 5% solution of glycolic acid results in damaged stratum corneum and skin corrosion. Treatment with Bromelain results in desquamation by digestion of the cells' envelope. In contrast, treatment with the hatching fluid composition of the invention results in desquamation by shedding of intact corneocytes because only the cell binding sites have been degraded. Thus, the hatching fluid solution provides gentle micro-exfoliation of the skin.
  • the hatching fluid composition of the invention has a skin rejuvenating effect and results in an improvement of skin barrier function.
  • Hatching fluid from non-Salmonidae fish species was analysed to determine whether it contains polypeptides that are equivalent to the polypeptides found in cosmetic compositions derived from Salmonidae hatching fluid.
  • An antibody was raised against a principle polypeptide component of the hatching fluid compositions described in Examples 1-3.
  • the antibody was used to determine whether similar polypeptides are present in hatching fluid from Medaka ( Oryzias latipes ) and Zebrafish ( Danio rerio ) .
  • Salmon hatching fluid was obtained according to the method described in Example 1.
  • Hatching fluid from Medaka and Zebrafish was obtained from the Zebrafish Laboratorium at the Department of Biology at the University of Bergen.
  • a sample of Zebrafish hatching fluid (30mL) was obtained from water in which approximately 100 embryos had hatched.
  • a sample of Medaka hatching fluid (14 mL) was obtained from water in which approximately 14 embryos had hatched. Water from an aquarium was used as a Blank control.
  • the samples were concentrated by freeze drying for 48 hours (approximately 10 fold) before analysis.
  • the protein concentration of the concentrated samples was measured in a Spectrophotometer at A280nm.
  • the concentrated polypeptide samples were analyzed by SDS-PAGE.
  • the resultant gels were stained by Coomassie blue or analyzed by Western blotting, using the aforementioned antibody against a principle component of the Salmon hatching fluid compositions.
  • the Coomassie stained gel in Figure 8A shows several clear bands for the Medaka sample (lane 2), which are comparable to the bands observed in the Salmon sample (lane 1). No visible bands were observed in the Blank sample (not shown) or the Zebrafish sample (lane 3). However, the absence of visible bands in the Zebrafish sample can be explained by the relatively low concentration of protein in the Zebrafish sample. Similarly, the presence of additional bands in the Salmon sample can be explained by the high concentration of protein in the Salmon sample, which means that even less abundant proteins are visible.
  • Figure 8B shows a Western blot which demonstrates that the antibody reacts specifically with a single band in the Salmon sample and cross-reacted with a protein in both the Medaka sample and the Zebrafish sample. Again, the difference in the intensity of the bands can be explained by the different concentration of protein in these samples.
  • the polypeptide identified in the Salmon sample was approximately 25kDa (lane 1).
  • the cross-reactive polypeptide in the Medaka sample was approximately 35 kDa (lane 2) and approximately 27kDa in the Zebrafish sample (lane 3). No polypeptides were detected by the antibody in the Blank sample (not shown).
  • the difference in the size of the polypeptides from Salmon, Medaka and Zebrafish may be attributed to interspecies variation and it is not uncommon for functionally equivalent polypeptides to vary in size in different species, for instance, due to different post-translational modifications such as glycosylation.
  • hatching fluid from each species contains a similar array of polypeptides and non-Salmonidae fish species contain polypeptides that are structurally similar to the polypeptides in the cosmetic compositions described in Examples 1-3.
  • the polypeptides in non-Salmonidae hatching fluid could be expected to have the same functional properties as the polypeptides in the cosmetic compositions derived from Salmon hatching fluid.
  • the hatching fluid from non-Salmonidae fish is a suitable starting material in the methods described herein and is expected to result in effective cosmetic compositions in accordance with the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP13815480.2A 2012-12-21 2013-12-19 A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin Active EP2934700B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1223330.0A GB201223330D0 (en) 2012-12-21 2012-12-21 Products, methods and uses
PCT/EP2013/077368 WO2014096187A2 (en) 2012-12-21 2013-12-19 A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin

Publications (2)

Publication Number Publication Date
EP2934700A2 EP2934700A2 (en) 2015-10-28
EP2934700B1 true EP2934700B1 (en) 2018-02-14

Family

ID=47682541

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13815480.2A Active EP2934700B1 (en) 2012-12-21 2013-12-19 A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin

Country Status (13)

Country Link
US (1) US10123967B2 (zh)
EP (1) EP2934700B1 (zh)
JP (1) JP2016503774A (zh)
KR (1) KR102210060B1 (zh)
CN (1) CN105007990B (zh)
AU (1) AU2013366643B2 (zh)
BR (1) BR112015015021B1 (zh)
CA (1) CA2895589C (zh)
ES (1) ES2661048T3 (zh)
GB (1) GB201223330D0 (zh)
HK (1) HK1210081A1 (zh)
RU (1) RU2015127474A (zh)
WO (1) WO2014096187A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819883D0 (en) * 2008-10-29 2008-12-03 Azyme Res As Product and uses
PE20150269A1 (es) 2012-01-23 2015-02-19 Restorsea Llc Composicion cosmetica que contiene una proteina de eclosion de huevo
CN105813627A (zh) 2013-12-13 2016-07-27 雷斯托尔西有限公司 脱落毛发保留促进的制剂
SG11201609241QA (en) 2014-05-16 2016-12-29 Restorsea Llc Biphasic cosmetic
CN111741758A (zh) * 2018-02-28 2020-10-02 株式会社极洋 可溶于生理学上可接受的液态介质的或以生理学上可接受的液态介质为提取介质提取的提取物及其制造方法
KR102017215B1 (ko) * 2018-02-28 2019-09-02 오서현 개복치 발효 추출물, 이를 포함하는 화장료 조성물 및 이의 제조방법
CN109329140A (zh) * 2018-12-17 2019-02-15 中国水产科学研究院黑龙江水产研究所 一种简化的青鳉受精卵孵化液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064384A1 (en) * 2009-11-30 2011-06-03 Aqua Bio Technology Asa Hatching fluid enzymes and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268499A (en) 1979-06-07 1981-05-19 Dow Corning Corporation Antiperspirant emulsion compositions
US5813963A (en) * 1995-12-29 1998-09-29 Fraser Box & Trading Co. Ltd. Method and apparatus for assembling roe containers
NO314594B1 (no) * 1997-12-11 2003-04-14 Aqua Bio Technology As Ikke-selvdegraderende endoprotease, fremgangsmåte for fremstilling samt anvendelser av denne
US7316817B2 (en) 2004-01-02 2008-01-08 New Medical Technologies, Inc. Method and device for topical delivery of therapeutic agents to the skin
US20080131493A1 (en) 2004-01-02 2008-06-05 Haitham Matloub Method and Multilayered Device for Controlled Topical Delivery of Therapeutic Agents to the Skin
DE102005053909A1 (de) 2005-05-13 2006-11-16 Beiersdorf Ag Selbstklebende Hautauflage und Kombinationsset zur kosmetischen Hautpflege
CN101184479B (zh) 2005-06-01 2011-05-04 尼普洛外用药品株式会社 贴剂
KR101230935B1 (ko) * 2006-10-31 2013-02-07 (주)아모레퍼시픽 경구용 피부 미용 개선용 조성물
GB0819883D0 (en) * 2008-10-29 2008-12-03 Azyme Res As Product and uses
KR101229927B1 (ko) * 2009-12-15 2013-02-05 이정호 잠사 추출물 또는 누에 추출물을 이용한 피부 미백제 조성물
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
PE20150269A1 (es) * 2012-01-23 2015-02-19 Restorsea Llc Composicion cosmetica que contiene una proteina de eclosion de huevo
BR112015014532B1 (pt) * 2012-12-21 2021-08-24 Aqua Bio Technology Asa Método para preparar uma composição cosmética de fluido de eclosão de peixe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064384A1 (en) * 2009-11-30 2011-06-03 Aqua Bio Technology Asa Hatching fluid enzymes and uses thereof

Also Published As

Publication number Publication date
ES2661048T3 (es) 2018-03-27
GB201223330D0 (en) 2013-02-06
US10123967B2 (en) 2018-11-13
CN105007990B (zh) 2018-04-06
CA2895589C (en) 2021-02-23
CA2895589A1 (en) 2014-06-26
ES2661048T8 (es) 2018-04-06
KR20150100819A (ko) 2015-09-02
AU2013366643A1 (en) 2015-07-16
BR112015015021B1 (pt) 2019-12-24
AU2013366643B2 (en) 2018-08-09
HK1210081A1 (zh) 2016-04-15
US20150328140A1 (en) 2015-11-19
WO2014096187A2 (en) 2014-06-26
EP2934700A2 (en) 2015-10-28
RU2015127474A (ru) 2017-01-26
KR102210060B1 (ko) 2021-02-01
WO2014096187A3 (en) 2014-08-28
JP2016503774A (ja) 2016-02-08
BR112015015021A2 (pt) 2017-07-11
CN105007990A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
US10987302B2 (en) Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin
EP2934700B1 (en) A cosmetic composition from fish hatching fluid, methods for its production and uses thereof for improving the cosmetic appearance of skin
US10556937B2 (en) Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
EP2934556B1 (en) Cosmetic and pharmaceutical compositions from fish hatching fluid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150720

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210081

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013033139

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61Q0019020000

Ipc: A61Q0019000000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/17 20060101ALI20170308BHEP

Ipc: A61Q 19/00 20060101AFI20170308BHEP

Ipc: A61K 8/02 20060101ALI20170308BHEP

Ipc: A61K 35/60 20060101ALI20170308BHEP

Ipc: A61Q 19/08 20060101ALI20170308BHEP

Ipc: A61K 8/98 20060101ALI20170308BHEP

Ipc: A61Q 19/02 20060101ALI20170308BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170503

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTC Intention to grant announced (deleted)
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

INTG Intention to grant announced

Effective date: 20180109

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013033139

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 969498

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2661048

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180327

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: AQUA BIO TECHNOLOGY ASA

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180214

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013033139

Country of ref document: DE

Owner name: AQUA BIO TECHNOLOGY ASA, NO

Free format text: FORMER OWNER: AQUA BIO TECHNOLOGY ASA, BERGEN, NO

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 969498

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180514

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180514

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013033139

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180214

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180614

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230802

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231218

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231228

Year of fee payment: 11

Ref country code: FR

Payment date: 20231219

Year of fee payment: 11

Ref country code: DE

Payment date: 20231220

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240118

Year of fee payment: 11